tocilizumab,cevostamab
roche
['220,mm,001', 'tocilizumab', 'toci', 'multiple myeloma', 'cevostamab']
lower rates of crs seen with prophylactic tocilizumab il-6 mo-ab in rrmm patients receiving the bcma/cd3 bispecific cevostamab by interfering with il-6 signaling . no observed negative impact on efficacy compared to retrospective control. watch for neutropenia. #ash22 
Multiple Myeloma Oncologist